Zacks Investment Research upgraded shares of PDL BIOPHARMA (PDLI) from UNDERPERFORM to NEUTRAL on December 14, 2012, with a target price of $7.70.
Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on PDL BIOPHARMA (PDLI),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment